Fоr Questiоn 36 tо 50 refer to the cаse below in order to аnswer the questions. Veridiа Pharmaceuticals — The 2024 Global Sustainability Report Veridia Pharmaceuticals is a large, publicly traded multinational pharmaceutical manufacturer headquartered in Chicago, Illinois, with manufacturing operations in the United States, Germany, India, and Brazil. Veridia produces both branded therapeutics and generic medicines, with annual revenues exceeding $18 billion. The company is listed on the NYSE and subject to full SEC reporting requirements, including Sections 302 and 404 of the Sarbanes-Oxley Act. Its 2024 Global Sustainability Report is 94 pages and opens with a CEO letter describing Veridia as "a company that holds itself to the highest standards of transparency and accountability across every dimension of our business." Environmental Disclosures Veridia's environmental disclosures are detailed. Scope 1 and Scope 2 greenhouse gas emissions are reported for all U.S. and German facilities, with a named third-party verifier and methodology disclosure. Scope 3 emissions are described as "under active measurement development" with a commitment to full reporting by 2027 and a named methodology framework in progress. Water withdrawal and wastewater discharge data are reported at the facility level for U.S. operations only, with a note stating that Indian and Brazilian facilities use municipal water systems and that data collection infrastructure is being developed. The company's 2030 net-zero commitment covers Scope 1 and 2 only. Social Disclosures Veridia reports a Total Recordable Incident Rate (TRIR) of 0.43 for its global workforce, verified by a named assurance provider under ISAE 3000. Employee training hours average 34.2 hours per employee annually across all facilities. Supply chain labor practices are reported through Veridia's annual supplier audit program. In 2024, 87% of tier-one suppliers completed scheduled audits. Two material non-compliance findings were identified — one related to excessive overtime hours at a contract manufacturing facility in India, and one related to inadequate grievance mechanisms at a packaging supplier in Brazil. Corrective action plans are in progress for both findings and will be reviewed at the next scheduled audit cycle. Tier-two supplier audit coverage is not yet in place; the report acknowledges this as a current limitation and states that a tier-two audit framework is under development. Access to medicines is addressed in two paragraphs. The report states that Veridia "is committed to expanding access to essential medicines in underserved markets" and participates in three named patient assistance programs in the United States. No pricing data, volume data, or geographic coverage metrics are disclosed for any market outside the United States. The report does not reference the SASB Biotechnology and Pharmaceuticals standard's disclosure requirement on drug pricing and access to medicines in low- and middle-income countries. Governance Disclosures The board of directors section states that Veridia's audit committee provides "robust and fully independent oversight of financial and non-financial reporting." The audit committee charter, publicly available in the proxy statement, assigns oversight responsibility for sustainability reporting to the full board rather than the audit committee specifically, with no named subcommittee and no disclosed meeting frequency on sustainability matters. ESG performance metrics are incorporated into executive compensation. The report states that "20% of annual incentive compensation for senior executives is evaluated based on ESG performance, assessed holistically across environmental, social, and governance criteria." No specific targets, baselines, or measurement methodology are disclosed for the ESG compensation component. A note in the governance section states that Veridia's Chief Sustainability Officer certifies the accuracy of all sustainability disclosures prior to publication. The CEO and CFO SOX Section 302 certifications filed with the SEC cover financial statement disclosures only and do not reference the sustainability report. Internal Controls Veridia's sustainability data is aggregated annually by the corporate sustainability team from facility-level submissions. Facility managers submit data using a standardized spreadsheet template. The corporate sustainability team reviews submissions for completeness and flags outliers for follow-up. There is no independent verification of facility-level inputs prior to aggregation, and the internal audit function has not reviewed the sustainability data aggregation process. The 2024 SOX 404(b) auditor attestation covers Veridia's internal controls over financial reporting only.